TABLE 1.
Clinical characteristics of the study population
| Variable | Subjects with histology proven renal TA-TMA (n=8) | HSCT recipients without renal TA-TMA on histology (n=12) |
|---|---|---|
| Age (years) | 3.7 (2.0–4.7) [0.6–5.0] | 3.2 (1.4–17.1) [0.9–28.1] |
| Gender (male) | 3 (37.5) | 8 (66.7) |
| Underlying diagnosisa | ||
| Malignancy | 6 (75.0) | 2 (16.7) |
| Immunodeficiency | 1 (12.5) | 9 (75.0) |
| Bone marrow failure | 1 (12.5) | 1 (8.3) |
| Type of transplanta | ||
| Allogeneic | 2 (25.0) | 11 (91.7) |
| Autologous | 6 (75.0) | 1 (8.3) |
| Type of conditioninga | ||
| Myeloablative | 7 (87.5) | 4 (33.3) |
| Reduced Intensity | 1 (12.5) | 8 (66.6) |
| GVHD in those at risk (allogeneic) | 1/2 (50) | 3/11 (27.3) |
| Viral infection | 4 (50.0) | 4 (33.3) |
| Dialysis | 6 (75) | 5 (41.7) |
| Day after HSCT of dialysis initiation (day+) | 163 (36–271) [1–2186] | 37 (16–79) [9–871] |
| Able to stop dialysis | 3/6 (50) | 0/5 (0) |
| Day after HSCT biopsy or autopsy | 233 (91–511) [19–2281] | 172 (78–453) [9–887] |
| specimen was obtained (day+) | ||
| Days after dialysis initiation biopsy or autopsy specimen was obtained | 51.5 (3–391) [j36 to 539] | 5 (3–17) [0–135] |
a
P<0.05 between cases and controls.
Data expressed as n (%) or median (25th–75th percentile) [range].
HSCT, hematopoietic stem cell transplant; GVHD, graft-versus-host disease; TA-TMA, transplant-associated thrombotic microangiopathy.